Atopic Dermatitis Treatment Market Projected To Grow With Significant CAGR Over The Forecast Period
Global atopic dermatitis treatment market: Atopic dermatitis is also known as Atopic Eczema. Atopic dermatitis is a type of inflammatory disease which is of unknown origin usually starts in early infancy, but also affects a major number of adults. Atopic dermatitis results in itchy, red, swollen and cracked skin. Many people with atopic dermatitis may develop hay fever and asthma. The causes are unknown but it is found to involve inherited, immune system dysfunction, environmental exposure and difficulties in permeability of skin. Multiple factors such as seasonal allergies, low humidity, exposure to harsh detergents & soaps, and cold weather can trigger or worsen atopic dermatitis. Atopic dermatitis treatment includes mainly steroid creams and moisturizers. Often, antibiotics are used when there is a skin infection. Diagnosis is done by physical examination and in some cases, biopsy is performed. Atopic Dermatitis treatment aims to control inflammation and relieving itching.
Global atopic dermatitis treatment market is driven by increased R & D funding to develop biologics and development of targeted therapies for atopic dermatitis. In addition increased incidence of atopic dermatitis, new product launches, and increased awareness about the symptoms of atopic dermatitis expected to further boost the atopic dermatitis treatment market. However, availability of the generic drugs and high cost of dermatology drugs are expected to hamper the atopic dermatitis treatment market.
Free sample of this report is available upon request @
Atopic dermatitis treatment market is categorized as following-
- Drug type
- Corticosteroids
- Calcineurin Inhibitors
- Immunosuppressants
- Phosphodiesterase type 4 (PDE-4) Inhibitors
- Antibiotics
- Antihistamines
- Emollients
- Route of administration
- Oral
- Topical
- Parenteral
Free TOC of this report is available upon request @
- End-users
Hospital Pharmacies, retail pharmacies and online pharmacies.
And lastly, on the basis of geographical regions, atopic dermatitis treatment market has been categorized into five regions- North America, Latin America, Asia-Pacific, Europe, and the Middle East &Africa. North America dominates atopic dermatitis treatment market, and is expected to show notable growth rates owing to product launches, lifestyle changes, and early treatment adoption. According to the National Eczema Association in the U.S., 31.6 million people are living with eczema. Europe atopic dermatitis market is growing due to large research and development activities. The Asia-Pacific market is expected to grow at a higher rate owing to rapid population growth, availability of large patient pool and changing lifestyle.
Some of the key market players in atopic dermatitis treatment market are Leo Pharma A/S (Denmark), Velite Pharmaceutical (India), Nestlé S.A. (Galderma SA) (Switzerland), Pfizer Inc. (U.S.), Anacor Pharmaceutical Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S), Sanofi S.A. (France), Novartis AG (Switzerland), Bayer AG (Germany), Mylan N.V. (Meda Pharmaceuticals) (U.S.), Bristol-Myers Squibb (BMS) (U.S), and Allergan Plc. (Ireland) to name a few. In 2017, Dupixent (Dupilumab), the first and only biologic medicine for the treatment of adults with moderate-to-severe atopic dermatitis, approved by USFDA. This drug was developed by Sanofi and Regeneron Pharmaceuticals in collaboration.
Ask Analyst for Full Information about this report @
Market players are focusing on R & D to discover new drugs to treat atopic dermatitis. Several global and regional players competing for the market share. Companies adopting several strategies such as acquisitions, mergers and partnering with other players to withstand the competition and grow their market share. For instance, AstraZeneca has entered into an agreement with LEO Pharma A/S, for the global license to Tralokinumab in skin diseases. Tralokinumab is a potential new medicine that is being developed in phase II clinical trials for the treatment of patients with atopic dermatitis. In 2016, Novartis acquired UK based Ziarco Group and expanded its R&D portfolio with once daily oral H4 receptor agonist, ZPL389, that is being developed for the treatment of atopic dermatitis. In addition, new classes of products are launched targeting atopic dermatitis other than the traditional classes such as corticosteroids. This gives the health care professionals to choose various alternatives. For instance, in February 2017, Pfizer got FDA approval for Eucris, a non-steroidal topical phosphodiesterase-4 inhibitor that is used for treatment of mild to moderate atopic dermatitis.
Get access to full summary @
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com